658710-29-3

Upstream product

• 13675-94-0 4-chloro-6-nitroquinoline 
• 79-37-8 oxalyl dichloride 
• 61203-48-3 2-iodo-4,5-dimethoxybenzoic acid 
• 658710-28-2 4-[[2-(dimethylamino)ethyl]amino]-6-nitroquinoline 
• 529-37-3 4(1H)-quinolinone 
• 21873-49-4 6-nitroquinoline-4(1H)-one 
• 113258-92-7 4,5-dimethoxy-2-iodobenzoyl chloride 

Relevant academic research and scientific papers

NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS

The invention provides compounds of formula 1 : wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula 1, processes for preparing compounds of formula 1, intermediates useful for preparing compounds of formula 1, and therapeutic methods for treating cancer using compounds of formula 1.

Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N, N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Influence on topoisomerase I-targeting activity and cytotoxicity

Recently, 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3- methylenedioxydibenzo[c,h][1,6]naphthyridin-6-one, 1, was identified as a TOP1-targeting agent with pronounced antitumor activity. In the present study, the effect on activity of substituting a

Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3- methylphenyl)acetamides: Selective dopamine D4 receptor agonists

Diaryl piperazine acetamides were identified as potent and selective dopamine D4 receptor agonists. Our strategy is based on an amide bond reversal of an acid sensitive, dopamine D4 receptor partial agonist, PD 168077. This reversal provided compounds with excellent potency and improved stability. Systematic evaluation of the substitution on the aryl piperazine portion revealed a significant effect on functional activity. The synthesis and biological activity of these new dopamine D4 agonists is discussed.